Northwestern Medicine scientists have uncovered a key pathway controlling tumor growth in B-cell lymphomas, according to a ...

Third, still other genes act on the ability of target tissues to modulate immune attack ... against cells bearing the cross-reacting self antigen. Molecular mimicry for T- and B-cell responses ...

Human populations that left Africa evolved quickly whereas Neanderthals stayed the same, according to an analysis of blood group systems.

When those T and B cells encounter a pathogen, the body needs the ones that recognize their antigen the best, with high ...

The FDA has approved Adcetris (brentuximab vedotin) for use in combination with lenalidomide and rituximab to treat patients with relapsed/refractory LBCL after 2 or more lines of systemic therapy who ...

Like CAR-T cell therapy, in which immune cells called T cells are harvested from the patient and genetically modified to attack ... chimeric antigen receptor natural killer cells in B-cell ...

A new study reveals that modifying the CUL5 gene enhances CAR-T cell therapy for leukemia and lymphoma. This improves cell ...

which developed in a patient with multiple myeloma after B-cell maturation antigen (BCMA) CAR T-cell therapy. A 72-year-old woman with relapsed, triple-class–refractory IgA kappa multiple ...

Study reveals how immune cells in the gut distinguish between food and harmful pathogens, shedding light on the origins of both food allergies and intestinal diseases.

The FDA has granted Fast Track designation to ADI-001 for the treatment of refractory systemic lupus erythematosus with extrarenal involvement.

"Who are you?" This question, in its many variations, is almost inevitable in school applications, job interviews or introspective moments. We spend years, perhaps our entire lives, unraveling the ...